Journal Article
. 2019 Oct; 19(1):954.
doi: 10.1186/s12885-019-6198-8.

Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial

Masaaki Kondo 1 Manabu Morimoto 2 Satoshi Kobayashi 3 Shinichi Ohkawa 3 Hisashi Hidaka 4 Takahide Nakazawa 4 Hiroshi Aikata 5 Takeshi Hatanaka 6 Daichi Takizawa 6 Kotaro Matsunaga 7 Chiaki Okuse 8 Michihiro Suzuki 8 Masataka Taguri 9 Takako Ishibashi 10 Kazushi Numata 2 Shin Maeda 11 Katsuaki Tanaka 2 
  • PMID: 31615466
  •     30 References
  •     11 citations


Background: The efficacy of hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma (HCC) remains unclear. We conducted a multi-center randomized phase II study comparing a sequential HAIC-sorafenib regimen versus sorafenib alone as an initial therapy for HCC.

Methods: Patients were randomly assigned (ratio, 1:1) to receive sequential HAIC with cisplatin followed by sorafenib (HAIC group, n = 35) or sorafenib alone (sorafenib group, n = 33) as an initial therapy. The primary endpoint was the one-year survival rate. Secondary endpoint included overall survival (OS), the 2-year survival rate, the time-to-progression (TTP), the objective response rate (ORR), the disease control rate (DCR), and safety.

Results: For the primary endpoint, the one-year survival rates were 46% in the HAIC group and 58% in the sorafenib group. The median OS period was 10.0 months (95% CI, 7.0-18.8) in the HAIC group and 15.2 months (95% CI, 8.2-19.7) in the sorafenib group (hazard ratio [HR], 1.08; 95% CI, 0.63 to 1.86, P = 0.78). The median TTP, ORR and DCR in the HAIC group were 2.8 months (95% CI, 1.7-5.5), 14.3, and 45.7%, respectively, while those in the sorafenib group were 3.9 months (95% CI, 2.3-6.8), 9.1, and 45.5%, respectively. No unexpected adverse events related to HAIC or sorafenib were observed in either group.

Conclusions: Sequential HAIC with cisplatin and sorafenib does not improve the survival benefit, compared with sorafenib alone, when used as an initial therapy for advanced HCC. However, this study was underpowered in regard to its primary and secondary endpoints, so the results should be interpreted with caution.

Trial Registration: UMIN ID 000006147 , registration data: August 11, 2011.

Keywords: Cisplatin; Hepatic arterial infusion chemotherapy; Hepatocellular carcinoma; Sequential treatment; Sorafenib.

5-fluorouracil arterial infusion + interferon therapy for highly advanced hepatocellular carcinoma: A multicenter, randomized, phase II study.
Morito Monden, Masato Sakon, +3 authors, FAIT Research Group.
Hepatol Res, 2011 Nov 03; 42(2). PMID: 22044786
Sorafenib in advanced hepatocellular carcinoma.
Josep M Llovet, Sergio Ricci, +22 authors, SHARP Investigators Study Group.
N Engl J Med, 2008 Jul 25; 359(4). PMID: 18650514
Highly Cited.
Hepatocellular carcinoma.
Alejandro Forner, Josep M Llovet, Jordi Bruix.
Lancet, 2012 Feb 23; 379(9822). PMID: 22353262
Highly Cited. Review.
Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion.
Shuntaro Obi, Haruhiko Yoshida, +7 authors, Masao Omata.
Cancer, 2006 Mar 28; 106(9). PMID: 16565970
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann-Lii Cheng, Yoon-Koo Kang, +18 authors, Zhongzhen Guan.
Lancet Oncol, 2008 Dec 20; 10(1). PMID: 19095497
Highly Cited.
Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib.
Manabu Morimoto, Kazushi Numata, +9 authors, Katsuaki Tanaka.
Hepatol Res, 2011 Feb 26; 41(4). PMID: 21348907
Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma.
Nicolas Williet, Léa Clavel, +5 authors, Jean-Marc Phelip.
Dig Liver Dis, 2017 Jul 18; 49(9). PMID: 28712860
Remission and survival following monthly intraarterial cisplatinum in nonresectable hepatoma.
Wayne S Court, Stanley E Order, +5 authors, Louis S Zeiger.
Cancer Invest, 2002 Aug 29; 20(5-6). PMID: 12197216
Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches.
Masato Sakon, Hiroaki Nagano, +7 authors, Morito Monden.
Cancer, 2002 Mar 20; 94(2). PMID: 11900229
Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma.
Masaharu Yoshikawa, Naofumi Ono, +2 authors, Hironobu Nakamura.
Hepatol Res, 2008 Apr 24; 38(5). PMID: 18430093
Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib.
Takeshi Terashima, Tatsuya Yamashita, +7 authors, Shuichi Kaneko.
Hepatol Res, 2013 Nov 01; 44(12). PMID: 24171787
Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy.
Masatoshi Kudo.
Liver Cancer, 2013 Oct 26; 1(2). PMID: 24159574    Free PMC article.
Hepatic arterial infusion therapy with a fine powder formulation of cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Masaaki Kondo, Manabu Morimoto, +2 authors, Katsuaki Tanaka.
Jpn J Clin Oncol, 2010 Aug 07; 41(1). PMID: 20688778
Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON.
Masatoshi Kudo, Masafumi Ikeda, +8 authors, Norihiro Kokudo.
J Gastroenterol, 2016 Apr 24; 51(12). PMID: 27106231    Free PMC article.
Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study.
Shuichi Kaneko, Kenji Ikeda, +7 authors, Kiwamu Okita.
J Gastroenterol, 2016 Mar 05; 51(10). PMID: 26931117    Free PMC article.
Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression.
Masaaki Kondo, Kazushi Numata, +5 authors, Katsuaki Tanaka.
Gastroenterol Res Pract, 2017 Jul 19; 2017. PMID: 28717362    Free PMC article.
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
Riccardo Lencioni, Josep M Llovet.
Semin Liver Dis, 2010 Feb 23; 30(1). PMID: 20175033
Highly Cited. Review.
Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors.
Koji Uchino, Ryosuke Tateishi, +7 authors, Kazuhiko Koike.
Cancer, 2011 Mar 26; 117(19). PMID: 21437884
Highly Cited.
Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib.
Takeshi Terashima, Tatsuya Yamashita, +9 authors, Shuichi Kaneko.
Hepatol Res, 2015 Oct 07; 46(7). PMID: 26441378
Catheter replacement of the needle in percutaneous arteriography; a new technique.
Acta radiol, 1953 May 01; 39(5). PMID: 13057644
Highly Cited.
Positive lymph node metastasis has a marked impact on the long-term survival of patients with hepatocellular carcinoma with extrahepatic metastasis.
Feng Xia, Lin Wu, +5 authors, Ping Bie.
PLoS One, 2014 Apr 25; 9(4). PMID: 24760012    Free PMC article.
Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma.
Augusto Villanueva, Josep M Llovet.
Hepatology, 2012 Dec 06; 56(6). PMID: 23212778
Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre.
A Grieco, M Pompili, +5 authors, G Gasbarrini.
Gut, 2005 Feb 16; 54(3). PMID: 15710992    Free PMC article.
Advances in targeted therapies for hepatocellular carcinoma in the genomic era.
Josep M Llovet, Augusto Villanueva, Anja Lachenmayer, Richard S Finn.
Nat Rev Clin Oncol, 2015 Jun 10; 12(7). PMID: 26054909
Highly Cited. Review.
Design and endpoints of clinical trials in hepatocellular carcinoma.
Josep M Llovet, Adrian M Di Bisceglie, +9 authors, Panel of Experts in HCC-Design Clinical Trials.
J Natl Cancer Inst, 2008 May 15; 100(10). PMID: 18477802
Highly Cited. Review.
Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma.
Kazuomi Ueshima, Masatoshi Kudo, +10 authors, Hobyung Chung.
Oncology, 2010 Jul 17; 78 Suppl 1. PMID: 20616598
Management of hepatocellular carcinoma: an update.
Jordi Bruix, Morris Sherman, American Association for the Study of Liver Diseases.
Hepatology, 2011 Mar 05; 53(3). PMID: 21374666    Free PMC article.
Highly Cited.
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.
Eiji Ando, Masatoshi Tanaka, +7 authors, Michio Sata.
Cancer, 2002 Sep 05; 95(3). PMID: 12209752
Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial.
M Ikeda, S Shimizu, +15 authors, T Okusaka.
Ann Oncol, 2016 Oct 30; 27(11). PMID: 27573564    Free PMC article.
Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
Lila Adnane, Pamela A Trail, Ian Taylor, Scott M Wilhelm.
Methods Enzymol, 2006 Jun 08; 407. PMID: 16757355
Highly Cited.
Targeted therapy for hepatocellular carcinoma.
Ao Huang, Xin-Rong Yang, +2 authors, Jian Zhou.
Signal Transduct Target Ther, 2020 Aug 13; 5(1). PMID: 32782275    Free PMC article.
Time to stop using hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma?-the SCOOP-2 trial experience.
Markus Peck-Radosavljevic, Simona Bota, Florian Hucke.
Ann Transl Med, 2020 Dec 15; 8(21). PMID: 33313085    Free PMC article.
Anti-PD-1 Immunotherapy Improves the Efficacy of Hepatic Artery Infusion Chemotherapy in Advanced Hepatocellular Carcinoma.
Jie Mei, Shao-Hua Li, +8 authors, Rong-Ping Guo.
J Hepatocell Carcinoma, 2021 Apr 02; 8. PMID: 33791252    Free PMC article.
Inhibition of mu-opioid receptor suppresses proliferation of hepatocellular carcinoma cells via CD147-p53-MAPK cascade signaling pathway.
Jia-Jia Zhang, Chang-Geng Song, +5 authors, Zhi-Nan Chen.
Am J Transl Res, 2021 Jun 22; 13(5). PMID: 34149993    Free PMC article.
Hepatic Arterial Infusion of Chemotherapy for Advanced Hepatobiliary Cancers: State of the Art.
Carmelo Laface, Mariarita Laforgia, +4 authors, Girolamo Ranieri.
Cancers (Basel), 2021 Jul 03; 13(12). PMID: 34205656    Free PMC article.
The past, present and future of conversion therapy for liver cancer.
Tianqiang Song, Mengran Lang, +2 authors, Wei Lu.
Am J Cancer Res, 2021 Nov 13; 11(10). PMID: 34765289    Free PMC article.
Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma.
Ching-Tso Chen, Tsung-Hao Liu, +3 authors, Zhong-Zhe Lin.
Int J Mol Sci, 2021 Dec 11; 22(23). PMID: 34884684    Free PMC article.
Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies.
Ellen Cusano, Chelsea Wong, +7 authors, Doreen Ezeife.
Curr Oncol, 2021 Dec 14; 28(6). PMID: 34898590    Free PMC article.
Neoadjuvant treatment strategies for hepatocellular carcinoma.
Lei Xu, Lin Chen, Wei Zhang.
World J Gastrointest Surg, 2022 Jan 25; 13(12). PMID: 35070063    Free PMC article.
Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study.
Qi Li, Mengran Cao, +9 authors, Jinzhang Chen.
Front Oncol, 2022 Mar 15; 12. PMID: 35280760    Free PMC article.
Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook.
Yinjie Fan, Hang Xue, Huachuan Zheng.
J Hepatocell Carcinoma, 2022 Apr 08; 9. PMID: 35388357    Free PMC article.